BDX Stock Forecast & Price Target

Becton Dickinson is continuing its strong performance with positive first quarter results and a solid outlook for the rest of the fiscal year. The company is strategically using funds for share repurchases and debt reduction and is also actively seeking out complementary acquisitions to further strengthen their position in high-growth markets. While there are potential risks, BD's management maintains a positive outlook and is committed to driving growth and value for their shareholders.

Becton Dickinson is a pure-play MedTech company with a sharpened strategic focus on high-growth end markets, recently completing the separation of its Biosciences & Diagnostics divisions to form a new company with Waters. While FY2026 guidance implies OMs lower than expectations, management expects to drive margin expansion (~30% OM over time) and accelerated revenue growth through their BD Excellence initiative, aiming to deliver average HSD EPS growth through the projected period to FY2030. Additionally, their capital allocation plan is balanced and strategically focused on growth, margin improvement, and shareholder returns, with an emphasis on share repurchases in the short- to medium-term.